News & Updates

A weekly treatment schedule of hypofractionated radiotherapy appears to yield good response rate in elderly patients with cutaneous squamous cell carcinoma (cSCC), while having minimal side effects, a study has shown.

Having an atopic eczema appears to slightly increase one’s risk of incident dementia, particularly among older adults, suggests a study. Such risk further grows with the severity of atopic eczema.

A recent study has identified three different clusters of bullous pemphigoid (BP), which includes one corresponding to severe BP180+ BP230− with features common to mucous membrane pemphigoid.

Very few patients with cutaneous lupus erythematosus (CLE) achieve long-term remission, which is negatively associated with active smoking and discoid CLE, reports a study.

Abrocitinib, the first janus kinase (JAK)1 inhibitor specifically indicated for the treatment of moderate-to-severe atopic dermatitis (AD), was recently approved in Singapore. During a webinar hosted by the Dermatological Society of Singapore, with the support of Pfizer, Professor Stephan Weidinger of University Hospital Scheswig-Holstein, Germany discussed several cases that exemplified appropriate patient selection for this novel agent.